All News

The combination SABA/ICS inhaler is the first of its kind and treats both acute bronchoconstriction and the inflammation that drives asthma and disease exacerbation.

The updated COVID-19 vaccines were approximately 54% effective against symptomatic SARS-CoV-2 infection, according to new data from the CDC.

In apixaban-treated participants, risk of stroke or systemic embolism was reduced by 37%; the risk of disability or fatal stroke declined by 49%, but with noted bleeding risk.

The 3-fold greater risk of subsequent stroke was observed in the Black Women's Health Study's youngest cohort, aged 24-34, investigators reported.

Your daily dose of the clinical news you may have missed.

Eating disorders among US youth spiked during the COVID-19 pandemic, but a new study shows hospitalizations have been inching up for a decade or more.

The risk of cough and asthma in persons with severe depression was 3.32 times and 2.84 times higher, respectively, than that in those without depression, reported researchers.

After March 8, 2024, EUA-labeled Paxlovid will no longer be authorized for use, regardless of expiration date, according to the agency.

Past month use of cannabis was associated with 43% greater odds of asthma than no use of the drug; odds were 2-fold greater with use of blunts.

Risk of mortality from ALD and MetALD was significantly higher among women even though both phenotypes were more prevalent among men, a new study reveals.

Reported adverse events of products with tianeptine include seizures, loss of consciousness, and death, according to the FDA.

Oral VX-548 has the potential to fill the gap between drugs that are tolerable but lack efficacy and opioids with therapeutic efficacy but known risks, according to Vertex.

Your daily dose of the clinical news you may have missed.

Measles cases are reported in 6 states, which is not a surprise to one pediatrician who points to the ongoing consequences of falling vaccination rates.

Low-dose calcium supplementation with 500 mg/day may be as protective against poor pregnancy outcomes as the WHO-recommended dose of 1500 mg/day.

New data suggest that dupilumab is safe for long-term use among patients with moderate-to-severe asthma or OCS-dependent severe asthma.

Your daily dose of the clinical news you may have missed.

The risk of asthma and poor outcomes was even greater among children with both conditions than among adults in this first study to compare the 2 populations.